Evidence map›Paper›PMID 29148540›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2018

Single-cell heterogeneity in ductal carcinoma in situ of breast.

Michael J Gerdes, Yesim Gökmen-Polar, Yunxia Sui, Alberto Santamaria Pang, Nicole LaPlante, Adrian L Harris, Puay-Hoon Tan, Fiona Ginty, Sunil S Badve

Abstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. AZGP1 deficiency promotes angiogenesis in prostate cancer.Journal of translational medicine · 2024
    Article
  4. Applicability of Spatial Technology in Cancer Research.Cancer research and treatment · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Improving DCIS diagnosis and predictive outcome by applying artificial intelligence.Biochimica et biophysica acta. Reviews on cancer · 2021
    Review
  14. Morphological intratumor heterogeneity in ductal carcinoma in situ of the breast.Virchows Archiv : an international journal of pathology · 2021
    Article
  15. Review
  16. Genomic Alterations during theMolecular cancer research : MCR · 2021
    Article
  17. Article
  18. Article
  19. Article
  20. Derivation of a nuclear heterogeneity image index to grade DCIS.Computational and structural biotechnology journal · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Michael J GerdesGE Global Research, Diagnostics, Imaging and Biotechnology (DIBT), Niskayuna, NY, USA.
Yesim Gökmen-PolarDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Yunxia SuiGE Global Research, Diagnostics, Imaging and Biotechnology (DIBT), Niskayuna, NY, USA.
Alberto Santamaria PangGE Global Research, Diagnostics, Imaging and Biotechnology (DIBT), Niskayuna, NY, USA.
Nicole LaPlante
Adrian L HarrisDepartment of Oncology, Cancer and Haematology Centre, Oxford University, Oxford, UK.
Puay-Hoon TanDivision of Pathology, Singapore General Hospital, Singapore.
Fiona GintyGE Global Research, Diagnostics, Imaging and Biotechnology (DIBT), Niskayuna, NY, USA.
Sunil S BadveDepartment of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.

Funding

(PQC3) Ethnicity-determined immune response and DCIS outcomeR01CA194600 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI BADVE, SUNIL S., GINTY, FIONA · 2015 to 2019
$2.7M
Cancer Research UK 11359Cancer Research UK 16466Cancer Research UK 18974Medical Research Council G0300648NCI NIH HHS R01 CA194600
6 · The paper itself

Abstract

Heterogeneous patterns of mutations and RNA expression have been well documented in invasive cancers. However, technological challenges have limited the ability to study heterogeneity of protein expression. This is particularly true for pre-invasive lesions such as ductal carcinoma in situ of the breast. Cell-level heterogeneity in ductal carcinoma in situ was analyzed in a single 5 μm tissue section using a multiplexed immunofluorescence analysis of 11 disease-related markers (EGFR, HER2, HER4, S6, pmTOR, CD44v6, SLC7A5 and CD10, CD4, CD8 and CD20, plus pan-cytokeratin, pan-cadherin, DAPI, and Na+K+ATPase for cell segmentation). Expression was quantified at cell level using a single-cell segmentation algorithm. K-means clustering was used to determine co-expression patterns of epithelial cell markers and immune markers. We document for the first time the presence of epithelial cell heterogeneity within ducts, between ducts and between patients with ductal carcinoma in situ. There was moderate heterogeneity in a distribution of eight clusters within each duct (average Shannon index 0.76; range 0-1.61). Furthermore, within each patient, the average Shannon index across all ducts ranged from 0.33 to 1.02 (s.d. 0.09-0.38). As the distribution of clusters within ducts was uneven, the analysis of eight ducts might be sufficient to represent all the clusters ie within- and between-duct heterogeneity. The pattern of epithelial cell clustering was associated with the presence and type of immune infiltrates, indicating a complex interaction between the epithelial tumor and immune system for each patient. This analysis also provides the first evidence that simultaneous analysis of both the epithelial and immune/stromal components might be necessary to understand the complex milieu in ductal carcinoma in situ lesions.

Indexed as

Biomarkers, TumorBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma in SituEpithelial CellsFemaleFluorescent Antibody TechniqueHumansNeoplasm ProteinsSingle-Cell AnalysisBiomarkers, TumorNeoplasm Proteins

Identifiers

PMID29148540
PMCPMC6192037

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.